October 27, 2017 Clinical Research/Diagn. Licensing, IP, and Legal Product Launch

New OCREVUS (ocrelizumab) data at ECTRIMS advance clinical understanding of underlying progression in multiple sclerosis

Basel, 27 October 2017 New OCREVUS (ocrelizumab) data at ECTRIMS advance clinical understanding of underlying progression in multiple sclerosis Data show superiority of OCREVUS compared to Rebif (interferon beta-1a) in significantly reducing disability Progression Independent of Relapse Activity (PIRA) in people with relapsing multiple sclerosis (RMS) Data demonstrates first method to automatically detect and characterise... Read more

October 27, 2017 Clinical Research/Diagn. Lab Top-10 Licensing, IP, and Legal

Release of Crossover Cath Lab System, Trinias unity edition Intervention Support with Real Time Image Processing Technology Covering Wide Range of Clinical Usage from Cardiac to Peripheral Region

Cath lab system is X-ray imaging system which is used under interventional treatment to treat patients with angina or cardiac infarct by using cathether. Intervention, which is less invasive treatment compared to surgery operation, recently attracts more attention, and more rapid development has been seen with downsizing and device qualification, reduction of contrast media, and... Read more

October 27, 2017 Clinical Research/Diagn. Lab Top-10 Licensing, IP, and Legal Microscopy

Release of Crossover Cath Lab System, Trinias unity edition Intervention Support with Real Time Image Processing Technology Covering Wide Range of Clinical Usage from Cardiac to Peripheral Region

Cath lab system is X-ray imaging system which is used under interventional treatment to treat patients with angina or cardiac infarct by using cathether. Intervention, which is less invasive treatment compared to surgery operation, recently attracts more attention, and more rapid development has been seen with downsizing and device qualification, reduction of contrast media, and... Read more

October 23, 2017 Lab Top-10 Licensing, IP, and Legal Life Science Tools

Canadian Patent Office to Grant MilliporeSigma’s Patent Application for CRISPR Technology

News Release October 23, 2017 Your Contact: Karen Tiano +1 978 495 0093 Patent covers successful integration of an external DNA sequence into the chromosome of eukaryotic cells using CRISPR First patent allowance for MilliporeSigma’s CRISPR technology in North America Related patent application awards by European and Australian Patent Offices already received; similar patents pending... Read more

October 16, 2017 Licensing, IP, and Legal PR/Corporate Product Launch

Roche to present new OCREVUS (ocrelizumab) efficacy and safety data in relapsing and primary progressive forms of multiple sclerosis at ECTRIMS

Basel, 16 October 2017 Roche to present new OCREVUS (ocrelizumab) efficacy and safety data in relapsing and primary progressive forms of multiple sclerosis at ECTRIMS Largest body of OCREVUS data presented at a congress to date reinforce favourable benefit-risk profile and advance clinical understanding of disease progression Roche (SIX: RO, ROG; OTCQX: RHHBY) announced today... Read more

October 16, 2017 Licensing, IP, and Legal PR/Corporate Product Launch

Roche to present new OCREVUS (ocrelizumab) efficacy and safety data in relapsing and primary progressive forms of multiple sclerosis at ECTRIMS

Basel, 16 October 2017 Roche to present new OCREVUS (ocrelizumab) efficacy and safety data in relapsing and primary progressive forms of multiple sclerosis at ECTRIMS Largest body of OCREVUS data presented at a congress to date reinforce favourable benefit-risk profile and advance clinical understanding of disease progression Roche (SIX: RO, ROG; OTCQX: RHHBY) announced today... Read more

September 28, 2017 Licensing, IP, and Legal

Roche’s OCREVUS (ocrelizumab) approved in Switzerland for primary progressive and relapsing forms of multiple sclerosis

Basel, 28 September 2017 Roche’s OCREVUS (ocrelizumab) approved in Switzerland for primary progressive and relapsing forms of multiple sclerosis OCREVUS is the first and only approved treatment for people with primary progressive MS, a highly disabling form of MS An important new treatment option for people with relapsing forms of MS demonstrating superior efficacy on... Read more

September 27, 2017 Clinical Research/Diagn. Licensing, IP, and Legal

Oxford Immunotec Announces Update in Patent Infringement Litigation

OXFORD, United Kingdom and MARLBOROUGH, Mass., September 27, 2017 (GLOBE NEWSWIRE) — Oxford Immunotec Global PLC (Nasdaq:OXFD), a global, high-growth diagnostics company focused on developing and commercializing proprietary tests for the management of underserved immune-regulated conditions, today announced a decision of the U.S. District Court for the District of Massachusetts in the Company’s patent infringement... Read more